Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502251 | 1.00 | FFAR2 (0.38) | FFAR2RAB9ARIPK1ADAM17MDM2 | |
| SCHEMBL2588030 | 0.88 | FFAR2 (0.39) | FFAR2RIPK1MDM2TP53CACNA1B | |
| SCHEMBL4514297 | 0.87 | RIPK1 (0.37) | RIPK1PDE5AHCAR2ADAMTS5 | |
| SCHEMBL4514302 | 0.87 | RIPK1 (0.37) | RIPK1PDE5AHCAR2ADAMTS5 | |
| SCHEMBL4513172 | 0.87 | MDM2 (0.35) | FFAR2MDM2HSD11B1HDAC8 | |
| SCHEMBL4513168 | 0.87 | MDM2 (0.35) | FFAR2MDM2HSD11B1HDAC8 | |
| SCHEMBL4087764 | 0.84 | FFAR2 (0.37) | FFAR2RIPK1 | |
| SCHEMBL4087759 | 0.84 | FFAR2 (0.37) | FFAR2RIPK1 | |
| SCHEMBL2588032 | 0.83 | FFAR2 (0.38) | FFAR2RIPK1ADAM17MDM2PDE5A | |
| SCHEMBL2588033 | 0.83 | FFAR2 (0.38) | FFAR2RIPK1ADAM17MDM2PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953158-B1 | BICYCLIC CINNAMIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | KIMURA TEIJI | 2009-07-16 | — | — | US | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | APP, BACE1, PSEN1 | FFAR2 3021/4885RAB9A 2810/4885RIPK1 4491/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | FFAR2 3021/4885RAB9A 2810/4885RIPK1 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.